posted on 2024-08-02, 05:44authored byLawrence
J. Liu, Bobby Lucero, Cindy Manriquez-Rodriguez, Karol R. Francisco, Thaiz R. Teixeira, Darius J. Yohannan, Carlo Ballatore, Samuel A. Myers, Anthony J. O’Donoghue, Conor R. Caffrey
The 20S proteasome is a multimeric protease complex that
is essential
for proteostasis in the cell. Small molecule proteasome inhibitors
are approved drugs for various cancers and are advancing clinically
as antiparasitics. Although tools and technologies to study the 20S
proteasome have advanced, only one probe is commercially available
to image proteasome activity. This probe consists of a fluorescently
labeled, peptidyl vinyl sulfone that binds to one or more of the catalytic
proteasome subunits. Here, we synthesized two, active site-directed
epoxyketone probes, LJL-1 and LJL-2, that were based on the peptidyl
backbones of the anticancer drugs, carfilzomib and bortezomib, respectively.
Each probe was conjugated, via click chemistry, to a bifunctional
group comprising 5-carboxytetramethylrhodamine (TAMRA) and biotin
to, respectively, visualize and enrich the 20S proteasome from protein
extracts of two eukaryotic pathogens, Leishmania donovani and Trichomonas vaginalis. Depending
on species, each probe generated a different subunit-binding profile
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE),
and the biotin tag enabled the enrichment of the bound subunits which
were then formally identified by proteomics. Species differences in
the order of electrophoretic migration by the β subunits were
also noted. Finally, both probes reacted specifically with the 20S
subunits in contrast to the commercial vinyl sulfone probe that cross
reacted with cysteine proteases. LJL-1 and LJL-2 should find general
utility in the identification and characterization of pathogen proteasomes,
and serve as reagents to evaluate the specificity and mechanism of
binding of new antiparasitic proteasome inhibitors.